Abbott Laboratories (ABT) stock
Health Care · Health Care Equipment
Abbott Laboratories (ABT) is a Health Care Equipment company in the Health Care sector, headquartered in North Chicago, Illinois. As of October 23, 2026, ABT closed at $103.70, a market capitalization of $179.44 billion, the 67th largest company in the S&P 500. Over the last twelve months it generated $48.23 billion in revenue (+14% year over year) and $7.38 billion in free cash flow. The stock trades at 38.6x trailing earnings and 17.4x forward earnings.
- 1-year total return: -15.9% (dividends reinvested)
- 5-year return: -2.0% a year
- 52-week range: $81.97 – $132.03
- Gross margin 57.1%, operating margin 11.3%
- Dividend yield: 2.43%, 12 straight years of increases
- FI Handbook report card: C+ across 9 metrics
- 9th largest of 60 Health Care stocks in the S&P 500
ABT price chart
1Y price change: -17.9% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| ABT | +0.8% | -15.2% | -15.9% | +4.9% | -2.0% | +11.9% | +14.7% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1980.
ABT key statistics
- Market cap
- $179.4B
- #67 in S&P 500
- P/E (TTM)
- 38.6x
- Forward P/E
- 17.4x
- EPS (TTM)
- $2.69
- Revenue (TTM)
- $48.2B
- +14%
- Free cash flow
- $7.4B
- Gross margin
- 57.1%
- Operating margin
- 11.3%
- Return on equity
- —
- Dividend yield
- 2.43%
- 52-week range
- $81.97 – $132.03
- Beta
- 0.58
- Price / sales
- 3.7x
- EV / EBITDA
- 17.3x
- Debt / equity
- 0.63x
- Employees
- 122,000
ABT report card
C+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth14.5%B
- Gross margin57.1%B
- Operating margin11.3%C
- FCF margin15.3%B
- Return on equity——
- Net debt / EBITDA2.3xD
- Forward P/E17.4xB
- PEG ratio2.1xD
- Shareholder yield2.9%C
- Share count change / yr-0.4%C
Abbott Laboratories financials
Revenue went from $20.9B in fiscal 2016 to $44.3B in fiscal 2025, growing 8.7% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.9B | $27.4B | $30.6B | $31.9B | $34.6B | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Gross profit | $11.8B | $15.0B | $17.9B | $18.7B | $19.6B | $24.5B | $24.5B | $22.1B | $23.2B | $25.0B |
| Operating income | $3.0B | $1.6B | $3.6B | $4.5B | $5.4B | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B |
| Net income | $1.4B | $477.0M | $2.4B | $3.7B | $4.5B | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| EPS (diluted) | $0.94 | $0.27 | $1.33 | $2.06 | $2.50 | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Free cash flow | $2.1B | $4.4B | $4.9B | $4.5B | $5.7B | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
| Buybacks | $522.0M | $117.0M | $238.0M | $718.0M | $403.0M | $2.3B | $3.8B | $1.2B | $1.3B | $893.0M |
| Dividends paid | $1.5B | $1.8B | $2.0B | $2.3B | $2.6B | $3.2B | $3.3B | $3.6B | $3.8B | $4.1B |
| Diluted shares | 1.5B | 1.7B | 1.8B | 1.8B | 1.8B | 1.8B | 1.8B | 1.7B | 1.7B | 1.7B |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into ABT?
A reverse DCF asks what growth the current price requires. With an enterprise value of $206.6B and $7.4B of trailing free cash flow, Abbott Laboratories needs to grow free cash flow about 19.1% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 5.3% a year over the last five years.
P/E ratio history
Current 27.9x vs. median 25.9x (10th–90th percentile 9.9x–60.5x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
ABT dividend
- Dividend yield
- 2.43%
- Annual dividend
- $2.52
- Years of increases
- 12
- 5-yr dividend growth
- 10.4%
- per year
- Payout ratio
- 79%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
ABT analyst price targets
26 analysts' average 12-month target is $118.52 (+14% vs. $103.70). Targets range from $100.00 to $130.00. 86% rate it a buy.
ABT earnings
Next report: January 28, 2027. Abbott Laboratories has beaten EPS estimates 7 quarters in a row.
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Oct 21, 2026 | $1.42 | $1.42 | +0.0% |
| Jul 16, 2026 | $1.28 | $1.31 | +2.6% |
| Apr 16, 2026 | $1.15 | $1.15 | +0.3% |
| Jan 22, 2026 | $1.49 | $1.50 | +0.3% |
| Oct 15, 2025 | $1.30 | $1.30 | +0.1% |
| Jul 17, 2025 | $1.26 | $1.26 | +0.3% |
| Apr 16, 2025 | $1.07 | $1.09 | +1.7% |
| Jan 22, 2025 | $1.34 | $1.34 | -0.2% |
Stocks like ABT
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ISRG Intuitive Surgical | +1.90% | -18% | $159.8B | 54.7x | Compare |
 MDT Medtronic plc. | -1.22% | +5% | $122.0B | 23.4x | Compare |
 SYK Stryker | +0.02% | -19% | $117.8B | 31.8x | Compare |
 BSX Boston Scientific | -0.70% | -55% | $66.2B | 18.5x | Compare |
 BDX Becton, Dickinson and | -0.75% | +39% | $54.2B | 46.3x | Compare |
 EW Edwards Lifesciences Corporatio | -1.13% | +16% | $51.3B | 53.0x | Compare |
 IDXX IDEXX Laboratories | -1.13% | -12% | $44.1B | 39.4x | Compare |
 RMD ResMed | -0.08% | -4% | $35.6B | 24.2x | Compare |
ABT news
- Abbott Laboratories (ABT) Posted Higher Sensitivity Data For Colorectal Cancer Recurrence Detection · Oct 24, 2026
- Clinical Laboratory Molecular Diagnostics for Infectious Diseases Market, 2025-2029: Forecast by Application, Place, and Country | Multiplex and Rapid Testing Unlock Growth · Oct 23, 2026
- Pacemakers Market Forecasts Growth from $5.4 Billion (2025) to $7.5 Billion by 2030, Profiling Medtronic, Abbott, Boston Scientific, Biotronik & 6 Other Key Players · Oct 23, 2026
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer · Oct 23, 2026
- Is Abbott Stock About To Rebound? · Oct 23, 2026
ABT stock FAQ
What is ABT's market cap?
Abbott Laboratories's market capitalization is $179.44 billion as of October 23, 2026, ranking 67th in the S&P 500.
What is ABT's P/E ratio?
ABT trades at a trailing price-to-earnings ratio of 38.6x and a forward P/E of 17.4x. Its median P/E over the period we track is 25.9x.
Does ABT pay a dividend?
Yes. Abbott Laboratories pays $2.52 per share a year, a 2.43% yield. It has raised its dividend 12 years in a row. Dividends grew 10.4% a year over the last five years.
How much has ABT stock returned?
Including reinvested dividends, ABT returned -15.9% over one year, -2.0% a year over five years, +11.9% a year over ten years through October 23, 2026.
Is ABT stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Abbott Laboratories must grow free cash flow about 19% a year for the next decade. Its free cash flow grew 5% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the ABT price target?
26 analysts cover ABT with an average 12-month price target of $118.52, +14% from the current price. 86% of them rate it a buy.
When does ABT report earnings?
Abbott Laboratories is expected to report earnings on January 28, 2027. It has beaten EPS estimates 7 quarters in a row.
How many employees does Abbott Laboratories have?
Abbott Laboratories has about 122,000 full-time employees, or $395,320 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology